市場調查報告書

近視 - 市場洞察,流行病學,預測 2028年

Myopia - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 787159
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
近視 - 市場洞察,流行病學,預測 2028年 Myopia - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

2018年的美國近視人口為9萬2,927人,市場規模推算為8,570萬美元。

本報告提供美國的近視市場相關調查,市場概要,總括性彙整概要和現行的治療方法,新藥的簡介,市場趨勢,流行病學的預測,市場規模,近視人口的變化與預測,流行病學的預測,市場規模,近視人口的變化與預測等資訊。

目錄

第1章 主要洞察

第2章 疾病概要:近視

  • 簡介
  • 症狀
  • 近視的分類
  • 近視的原因
  • 近視的病理生理學
  • 近視的診斷
  • 風險與併發症

第3章 流行病學和患者人口

  • 主要調查結果

第4章 美國 - 近視的流行病學

  • 假設和理論的根據
  • 近視的總人口
  • 近視的人口:各年齡
  • 近視的人口:性別
  • 兒童近視的人口:嚴重度別
  • 成人近視的人口:嚴重度別

第5章 現行的治療方法

  • 進行性近視的治療方法選擇
  • 近視矯正的管理策略

第6章 未滿足需求

第7章 新藥

  • 交叉競爭
  • NVK-002:Nevakar
    • 產品概要
    • 其他開發活動
    • 臨床開發
    • 優點與缺點
    • 產品簡介
  • MicroPine:Eyenovia
    • 安全性和有效性

第8章 美國的近視市場分析

  • 主要調查結果

第1章 各國市場預測

第2章 美國市場:市場預測

  • 整體市場規模
  • 市場規模:各治療藥物

第3章 成長要素

第4章 進入障礙

第5章 附錄

第6章 DelveInsight的服務內容

第7章 免責聲明

第8章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0505

DelveInsight's "Myopia - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Myopia, historical and forecasted epidemiology as well as the Myopia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Myopia market report provides current treatment practices, emerging drugs, Myopia market share of the individual therapies, current and forecasted Myopia market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Myopia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Myopia Disease Understanding and Treatment Algorithm

The DelveInsight Myopia market report gives a thorough understanding of the Myopia by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Myopia.

Treatment

It covers the details of conventional and current medical therapies available in the Myopia market for the treatment of the condition. It also provides Myopia treatment algorithms and guidelines in the United States, Europe, and Japan.

Myopia Epidemiology

The Myopia epidemiology division provide insights about historical and current Myopia patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Myopia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Myopia Epidemiology

The epidemiology segment also provides the Myopia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Myopia Drug Chapters

Drug chapter segment of the Myopia report encloses the detailed analysis of Myopia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Myopia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Myopia treatment.

Myopia Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Myopia treatment.

Myopia Market Outlook

The Myopia market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Myopia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Myopia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Myopia market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Myopia market in 7MM.

The United States Market Outlook

This section provides the total Myopia market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Myopia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Myopia market size and market size by therapies in Japan is also mentioned.

Myopia Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Myopia market or expected to get launched in the market during the study period 2017-2030. The analysis covers Myopia market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Myopia Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Myopia key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Myopia emerging therapies.

Reimbursement Scenario in Myopia

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Myopia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Myopia market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Myopia Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Myopia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Myopia epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Myopia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Myopia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Myopia market

Report Highlights

  • In the coming years, Myopia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Myopia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Myopia. Launch of emerging therapies will significantly impact the Myopia market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Myopia
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Myopia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Myopia Pipeline Analysis
  • Myopia Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Myopia Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Myopia Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Myopia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Myopia market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Myopia total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Myopia market size during the forecast period (2017-2030)?
  • At what CAGR, the Myopia market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Myopia market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Myopia market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Myopia?
  • What is the historical Myopia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Myopia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Myopia?
  • Out of all 7MM countries, which country would have the highest prevalent population of Myopia during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Myopia treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Myopia in the USA, Europe, and Japan?
  • What are the Myopia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Myopia?
  • How many therapies are developed by each company for Myopia treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Myopia treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Myopia therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Myopia and their status?
  • What are the key designations that have been granted for the emerging therapies for Myopia?
  • What are the global historical and forecasted market of Myopia?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Myopia market
  • To understand the future market competition in the Myopia market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Myopia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Myopia market
  • To understand the future market competition in the Myopia market

Table of Contents

1. Key Insights

2. Executive Summary of Myopia

3. Competitive Intelligence Analysis for Myopia

4. Myopia: Market Overview at a Glance

  • 4.1. Myopia Total Market Share (%) Distribution in 2017
  • 4.2. Myopia Total Market Share (%) Distribution in 2030

5. Myopia: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Myopia Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Myopia Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Myopia Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Myopia Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Myopia Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Myopia Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Myopia Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Myopia Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Myopia Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Myopia Treatment and Management
  • 8.2. Myopia Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Myopia Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Myopia: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Myopia Market Size in 7MM
  • 13.3. Myopia Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Myopia Total Market Size in the United States
    • 15.1.2. Myopia Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Myopia Total Market Size in Germany
    • 15.3.2. Myopia Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Myopia Total Market Size in France
    • 15.4.2. Myopia Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Myopia Total Market Size in Italy
    • 15.5.2. Myopia Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Myopia Total Market Size in Spain
    • 15.6.2. Myopia Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Myopia Total Market Size in the United Kingdom
    • 15.7.2. Myopia Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Myopia Total Market Size in Japan
    • 15.8.3. Myopia Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Myopia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Myopia Epidemiology (2017-2030)
  • Table 2 : 7MM Myopia Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Myopia Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Myopia Epidemiology in Germany (2017-2030)
  • Table 6 : Myopia Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Myopia Epidemiology in France (2017-2030)
  • Table 8 : Myopia Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Myopia Epidemiology in Italy (2017-2030)
  • Table 10 : Myopia Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Myopia Epidemiology in Spain (2017-2030)
  • Table 12 : Myopia Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Myopia Epidemiology in the UK (2017-2030)
  • Table 14 : Myopia Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Myopia Epidemiology in Japan (2017-2030)
  • Table 16 : Myopia Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Myopia Epidemiology (2017-2030)
  • Figure 2 : 7MM Myopia Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Myopia Epidemiology in the United States (2017-2030)
  • Figure 4 : Myopia Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Myopia Epidemiology in Germany (2017-2030)
  • Figure 6 : Myopia Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Myopia Epidemiology in France (2017-2030)
  • Figure 8 : Myopia Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Myopia Epidemiology in Italy (2017-2030)
  • Figure 10 : Myopia Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Myopia Epidemiology in Spain (2017-2030)
  • Figure 12 : Myopia Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Myopia Epidemiology in the UK (2017-2030)
  • Figure 14 : Myopia Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Myopia Epidemiology in Japan (2017-2030)
  • Figure 16 : Myopia Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)